Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC grew its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 11.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 14,581 shares of the company’s stock after purchasing an additional 1,491 shares during the period. Natixis Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $1,051,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of PBH. Opal Wealth Advisors LLC acquired a new position in Prestige Consumer Healthcare during the 2nd quarter valued at about $26,000. Quest Partners LLC raised its holdings in Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares in the last quarter. Gladius Capital Management LP acquired a new stake in Prestige Consumer Healthcare in the second quarter worth approximately $35,000. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the company. DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $83.18 on Wednesday. Prestige Consumer Healthcare Inc. has a 1 year low of $56.61 and a 1 year high of $86.36. The business’s fifty day moving average is $74.76 and its two-hundred day moving average is $70.88. The stock has a market capitalization of $4.11 billion, a P/E ratio of 20.24, a P/E/G ratio of 2.39 and a beta of 0.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the previous year, the firm earned $1.07 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.